These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 27775703)
1. DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Parrales A; Ranjan A; Iyer SV; Padhye S; Weir SJ; Roy A; Iwakuma T Nat Cell Biol; 2016 Nov; 18(11):1233-1243. PubMed ID: 27775703 [TBL] [Abstract][Full Text] [Related]
2. The interplay between mutant p53 and the mevalonate pathway. Parrales A; Thoenen E; Iwakuma T Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070 [TBL] [Abstract][Full Text] [Related]
3. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY J Biol Chem; 2021; 296():100098. PubMed ID: 33208462 [TBL] [Abstract][Full Text] [Related]
4. DNAJA1 promotes cancer metastasis through interaction with mutant p53. Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772 [TBL] [Abstract][Full Text] [Related]
5. Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin. Alalem M; Bhosale M; Ranjan A; Yamamoto S; Kaida A; Nishikawa S; Parrales A; Farooki S; Anant S; Padhye S; Iwakuma T Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077724 [TBL] [Abstract][Full Text] [Related]
6. DNAJA1- and conformational mutant p53-dependent inhibition of cancer cell migration by a novel compound identified through a virtual screen. Nishikawa S; Kaida A; Parrales A; Ranjan A; Alalem M; Ren H; Schoenen FJ; Johnson DK; Iwakuma T Cell Death Discov; 2022 Oct; 8(1):437. PubMed ID: 36316326 [TBL] [Abstract][Full Text] [Related]
7. Key roles of Rho GTPases, YAP, and Mutant P53 in anti-neoplastic effects of statins. Ji L; Liu C; Yuan Y; Gao H; Tang ZX; Yang Z; Liu ZT; Jiang GH Fundam Clin Pharmacol; 2020 Feb; 34(1):4-10. PubMed ID: 31241783 [TBL] [Abstract][Full Text] [Related]
8. APE1/Ref-1 enhances DNA binding activity of mutant p53 in a redox-dependent manner. Cun Y; Dai N; Li M; Xiong C; Zhang Q; Sui J; Qian C; Wang D Oncol Rep; 2014 Feb; 31(2):901-9. PubMed ID: 24297337 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53. Xu D; Tong X; Sun L; Li H; Jones RD; Liao J; Yang GY Mol Carcinog; 2019 Nov; 58(11):2052-2064. PubMed ID: 31397499 [TBL] [Abstract][Full Text] [Related]
11. Regulation of p53 and Cancer Signaling by Heat Shock Protein 40/J-Domain Protein Family Members. Kaida A; Iwakuma T Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948322 [TBL] [Abstract][Full Text] [Related]
12. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma. Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964 [TBL] [Abstract][Full Text] [Related]
13. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53. Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266 [TBL] [Abstract][Full Text] [Related]
14. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Göhler T; Jäger S; Warnecke G; Yasuda H; Kim E; Deppert W Nucleic Acids Res; 2005; 33(3):1087-100. PubMed ID: 15722483 [TBL] [Abstract][Full Text] [Related]
16. Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion. Zhang S; Wang C; Ma B; Xu M; Xu S; Liu J; Tian Y; Fu Y; Luo Y Cell Rep; 2020 Jul; 32(1):107879. PubMed ID: 32640214 [TBL] [Abstract][Full Text] [Related]
17. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011 [TBL] [Abstract][Full Text] [Related]
18. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8. Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563 [TBL] [Abstract][Full Text] [Related]
19. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations. Meng X; Gao JZ; Gomendoza SMT; Li JW; Yang S Front Med (Lausanne); 2021; 8():737951. PubMed ID: 34671620 [TBL] [Abstract][Full Text] [Related]
20. DNAJA1 promotes proliferation and metastasis of breast cancer by activating mutant P53/NF-κB pathway. Wu J; Yang Q; Zhu Y; Xia T; Yi L; Wang J; Ren X Pathol Res Pract; 2023 Dec; 252():154921. PubMed ID: 37977037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]